Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

        Drug Safety and Availability

Food and Drug Administration Overdose Prevention Framework Home
          Drugs
          Drug Safety and Availability
          Food and Drug Administration Overdose Prevention FrameworkDrug Safety and Availability Food and Drug Administration Overdose Prevention Framework
  	
        Share
    Post
    Linkedin

    Email
    PrintOverdose Prevention Activities

FDA announces shelf-life extension for naloxone nasal spray
	FDA opens funding opportunity seeking applications to support human abuse potential study of botanical kratom
	FDA approves safety labeling changes for opioid pain medicines

The FDA Overdose Prevention Framework consists of four overarching priorities that align with the **U.S. Department of Health & Human Services' Overdose Prevention Strategy** to address the public health emergency as it continues to evolve. The overdose crisis is an evolving public health crisis; as such, FDA continues to evaluate our approach and make adjustments according to the latest available science and data.

FDA Overdose Prevention Framework

FDA’s Overdose Prevention Framework Priorities

Supporting primary prevention by eliminating unnecessary initial prescription drug exposure and inappropriate prolonged prescribing.
	Encouraging harm reduction through innovation and education.
	Advancing development of evidence-based treatments for substance use disorders.
	Protecting the public from unapproved, diverted, or counterfeit drugs presenting overdose risks.Overdose Prevention Activities Timeline

Chronological information about significant FDA activities related to substance use and overdose prevention.

United States Government Partners
	Centers for Disease Control and Prevention (CDC)
	Centers for Medicare & Medicaid Services (CMS)
	Customs and Border Protection (CPB)
	Drug Enforcement Administration (DEA)
	Indian Health Service (IHS)
	Health & Human Services (HHS)
	National Institutes of Health (NIH)
	Substance Abuse and Mental Health Services Administration (SAMHSA)
	Veterans Affairs (VA)
Sub-Topic Paragraphs
          FDA PrioritiesSupporting

                    Supporting Primary Prevention
            Supporting primary prevention by eliminating unnecessary initial prescription drug exposure and inappropriate prolonged prescribing.
          
          Encouraging

                    Encouraging Harm Reduction
            Encouraging harm reduction through innovation and education.
    
          Advancing

                    Advancing Evidence-Based Treatments
            Advancing development of evidence-based treatments for substance use disorders.
    
          Protecting

                    Protecting the Public from Unapproved, Diverted, or Counterfeit Drugs presentin...
            Protecting the public from unapproved, diverted, or counterfeit drugs presenting overdose risks.
          Related ResourcesSafe Opioid Disposal - Remove the Risk Outreach ToolkitHHS: Help and Resources National Opioids CrisisCDC: Injury Prevention and Control: Prescription Drug OverdoseSubstance Abuse and Mental Health Services Administration: OpioidsNational Institute on Drug Abuse: OpioidsSearch and Rescue: Connecting prescribers to resources to help prevent drug mis...

                                                                                  Content current as of:
      01/17/2024
                  
                   
Regulated Product(s)
		 DrugsFood and Drug Administration Overdose Prevention Framework
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop